Malignant Lymphoma
Conditions
Interventions
we use palonosetron as anti-emesis drug, and ask patients to fill out an emesis diary
Sponsors
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)The patients who are historically confirmed as Non-Hodgikin Lymphoma, and planed to treat with (R-)CHOP regimen 2)The patients who don't have nausea or vomiting 3)The patients who have not been treated with chemotherapy 4)The patients who are expected to survive more than 3 months 5)The patients whose ECOG performance status are 0 to 2 6)The patients who are able to fill out an emesis diary 7)The patients who are more than 18 years old, and agree to participate in this study with document
Exclusion criteria
Exclusion criteria: 1)The patients who will have nausea and vomiting except for chemotherapy 2)The patients who have contraindication to use palonocetron 3)The patients who need to reduce CHOP regimen 4)The patients who need to reduce or stop to use prednisolone 5)The patients who are HIV antibody positive, HBs antigen positive, or HCV antibody positive 6)The patients whose doctor judge as ineligible
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of nausea, vomiting, and anorexia | — |
Countries
Japan
Contacts
Public ContactYoshiharu Miyata
Department of Medicine, Kobe University Graduate School of Medicine Division of Medical Oncology/Hematology
Outcome results
None listed